These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 27932158)

  • 21. Incidence of donor-specific antibodies in kidney transplant patients following conversion to an everolimus-based calcineurin inhibitor-free regimen.
    Kamar N; Del Bello A; Congy-Jolivet N; Guilbeau-Frugier C; Cardeau-Desangles I; Fort M; Esposito L; Guitard J; Gamé X; Rostaing L
    Clin Transplant; 2013; 27(3):455-62. PubMed ID: 23621682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of the Combination of Everolimus and Tacrolimus With High Dosage of Mizoribine for Living Donor-Related Kidney Transplantation.
    Yoshimura N; Nakao T; Nakamura T; Harada S; Koshino K; Suzuki T; Ito T; Nobori S; Ushigome H
    Transplant Proc; 2016 Apr; 48(3):786-9. PubMed ID: 27234736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sirolimus and tacrolimus coefficient of variation is associated with rejection, donor-specific antibodies, and nonadherence.
    Pizzo HP; Ettenger RB; Gjertson DW; Reed EF; Zhang J; Gritsch HA; Tsai EW
    Pediatr Nephrol; 2016 Dec; 31(12):2345-2352. PubMed ID: 27286686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence of Donor-Specific Anti-HLA Antibodies in Non-HLA-Sensitized Patients Given Tacrolimus Once or Twice Daily During the First 2 Years After Kidney Transplant.
    Hage V; Ferrandiz I; Béllière J; Esposito L; Hebral AL; Cointault O; Del Bello A; Kamar N
    Exp Clin Transplant; 2019 Jun; 17(3):313-319. PubMed ID: 30602364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Higher Serum Trough Levels of Tacrolimus Increase 5-Year Allograft Survival in Antibody Positive Renal Transplant Patients.
    Peng ZG; Tian J
    Clin Transpl; 2014; ():209-14. PubMed ID: 26281147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Everolimus: a guide to its use in liver transplantation.
    Keating GM; Lyseng-Williamson KA
    BioDrugs; 2013 Aug; 27(4):407-11. PubMed ID: 23696253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Experience with the use of sirolimus in liver transplantation--use in patients for whom calcineurin inhibitors are contraindicated.
    Chang GJ; Mahanty HD; Quan D; Freise CE; Ascher NL; Roberts JP; Stock PG; Hirose R
    Liver Transpl; 2000 Nov; 6(6):734-40. PubMed ID: 11084060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tacrolimus prolonged release (Envarsus®): a review of its use in kidney and liver transplant recipients.
    Garnock-Jones KP
    Drugs; 2015 Feb; 75(3):309-20. PubMed ID: 25613762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pilot Randomized Trial of Tacrolimus/Everolimus vs Tacrolimus/Enteric-Coated Mycophenolate Sodium in Adult, Primary Kidney Transplant Recipients at a Single Center.
    Ciancio G; Tryphonopoulos P; Gaynor JJ; Guerra G; Sageshima J; Roth D; Chen L; Kupin W; Mattiazzi A; Tueros L; Flores S; Hanson L; Powell RH; Ruiz P; Vianna R; Burke GW
    Transplant Proc; 2016; 48(6):2006-10. PubMed ID: 27569936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
    Jones-Hughes T; Snowsill T; Haasova M; Coelho H; Crathorne L; Cooper C; Mujica-Mota R; Peters J; Varley-Campbell J; Huxley N; Moore J; Allwood M; Lowe J; Hyde C; Hoyle M; Bond M; Anderson R
    Health Technol Assess; 2016 Aug; 20(62):1-594. PubMed ID: 27578428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients--a three-yr serial echocardiographic substudy of the randomized controlled CENTRAL trial.
    Murbraech K; Massey R; Undset LH; Midtvedt K; Holdaas H; Aakhus S
    Clin Transplant; 2015 Aug; 29(8):678-84. PubMed ID: 25982053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Graft immunologic events in deceased donor kidney transplant recipients with preformed HLA-donor specific antibodies.
    Ixtlapale-Carmona X; Arvizu A; De-Santiago A; González-Tableros N; López M; Castelán N; Marino LA; Uribe-Uribe NO; Contreras AG; Vilatobá M; Morales-Buenrostro LE; Alberú J
    Transpl Immunol; 2018 Feb; 46():8-13. PubMed ID: 28974434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
    Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
    Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction Immunosuppressive Therapy With Everolimus and Low-Dose Tacrolimus Extended-Release Preserves Good Renal Function at 1 Year After Kidney Transplantation.
    Yamanaka K; Kakuta Y; Nakazawa S; Kato T; Abe T; Imamura R; Okumi M; Ichimaru N; Kyo M; Kyakuno M; Takahara S; Nonomura N
    Transplant Proc; 2016 Apr; 48(3):781-5. PubMed ID: 27234735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging drugs for prevention of T-cell mediated rejection in liver and kidney transplantation.
    Wong TC; Lo CM; Fung JY
    Expert Opin Emerg Drugs; 2017 Jun; 22(2):123-136. PubMed ID: 28503959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Once daily everolimus is safe and effective in de novo renal transplant recipients: six-month results of a pilot study.
    Favi E; Spagnoletti G; Gargiulo A; Salerno MP; Romagnoli J; Citterio F
    Transplant Proc; 2010 May; 42(4):1308-11. PubMed ID: 20534287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities.
    Pascual J; Diekmann F; Fernández-Rivera C; Gómez-Marqués G; Gutiérrez-Dalmau A; Pérez-Sáez MJ; Sancho-Calabuig A; Oppenheimer F
    Nefrologia; 2017; 37(3):253-266. PubMed ID: 28551032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with rituximab, splenectomy, and bortezomib.
    Koch M; Gräser C; Lehnhardt A; Pollok JM; Kröger N; Verboom M; Thaiss F; Eiermann T; Nashan B
    Transpl Int; 2013 Aug; 26(8):e64-8. PubMed ID: 23672514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
    Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
    Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perioperative Desensitization Improves Outcomes Among Crossmatch Positive Recipients of Deceased Donor Renal Transplants.
    Sharma A; King A; Kumar D; Behnke M; McDougan F; Kimball PM
    Prog Transplant; 2016 Jun; 26(2):157-61. PubMed ID: 27207404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.